Regulation, by its nature, is cautious. Agencies tasked with protecting public health are not designed to move fast; they are designed to be rigorous. Yet rare diseases have, from the very beginning, placed regulators in an uncomfortable position.
The same caution that protects patients from unsafe or ineffective treatments also, if applied without adaptation, denies those same patients access to therapies that might meaningfully transform their lives – therapies that, given the size of the populations involved, may never achieve the volume of clinical evidence that conventional standards demand. Managing that tension has been the central regulatory challenge in rare diseases for over four decades, and it is the challenge that has driven regulators, step by step, toward an increasingly collaborative engagement with rare disease networks.
The Starting Point: Flexibility Within a Safety Framework
The regulatory story in rare diseases begins, as so much else does, with the 1983 Orphan Drug Act in the United States. The Act did not merely provide commercial incentives to pharmaceutical companies – it created the FDA’s Office of Orphan Products Development (OOPD), an institutional acknowledgement that rare diseases required dedicated regulatory infrastructure rather than ad hoc accommodation within frameworks designed for mainstream medicine.
Prior to 1983, fewer than twelve drugs existed for all rare diseases combined. The OOPD’s mandate was to change that, and it has done so with striking results: by 2024, more than 1,200 drugs had been approved for rare diseases, compared to that handful forty years earlier. But approval numbers tell only part of the story. The more significant regulatory evolution has been in how agencies now think about evidence – what counts, where it comes from, and who contributes to generating it.
The balancing act this requires was captured clearly by former FDA Acting Commissioner Janet Woodcock at the 2021 National Organization for Rare Disorders (NORD) Breakthrough Summit. Acknowledging the statistical impossibility of conventional trial standards for very small patient populations, she noted: “The FDA often exercises greater regulatory flexibility, in particular by accepting clinical trials that have lower sample sizes,” while stressing that the goal remained to “minimise bias and maximise precision” through careful design. That principle – flexibility without abandonment of the safety mandate – captures the tightrope that regulators have walked ever since, and explains why rare disease networks have become so important to how that balance is struck in practice.
The Evidence Problem – and the Network Solution
The fundamental challenge for rare disease regulators is not philosophical but statistical. Conventional drug approval depends on large, well-powered randomised controlled trials that can demonstrate safety and efficacy with a high degree of confidence. In rare diseases, such trials are frequently impossible: patient populations are simply too small, too geographically dispersed, and too heterogeneous.
As Peter Marks, former Director of the FDA’s Center for Biologics Evaluation and Research, observed: “There are many rare diseases affecting dozens to a few hundred individuals in the United States where the concept of trying to do a randomised trial is very challenging at best and impossible at worst.” A regulator demanding conventional evidence standards in this environment is not being rigorous – they are being impractical, and the patients who need treatment will pay the price.
The solution that has emerged over decades is not to lower the bar for safety and efficacy, but to enrich the quality and diversity of the evidence that regulators accept. Patient registries maintained by rare disease networks document natural disease histories over years – exactly the kind of longitudinal data that can serve as an external comparator when a randomised control arm is not feasible. The FDA supports programmes aimed at developing alternative data sources, notably the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP), a centralised database containing standardised data on a growing number of rare diseases that allows secure sharing across multiple sources, including natural history studies, patient registries, and real-world data.
This is not a concession to scientific compromise. It is a recognition that the networks surrounding rare diseases have been quietly generating the most rigorous evidence available – and that regulators who fail to engage with those networks are making their own job harder while denying patients the benefit of data that already exists.
Patient-Focused Development: Outcomes That Actually Matter
Perhaps the most significant shift in regulatory thinking over the past two decades has been on the question of what drug development is ultimately for. Translating that principle into regulatory practice has required sustained effort and, crucially, the structured involvement of patient communities that only rare disease networks could provide.
The FDA’s Patient-Focused Drug Development (PFDD) initiative, established under the fifth authorisation of the Prescription Drug User Fee Act and launched in 2012, hosted 24 disease-specific public meetings between 2012 and 2017, at which patients and caregivers described in their own terms what mattered most – not the endpoints that are easiest to measure, but the functional limitations, quality-of-life impacts, and treatment trade-offs that shaped their daily reality.
This matters enormously in the context of rare disease networks. Clinical outcomes defined without patient input have repeatedly proven to be poor proxies for what patients actually need. A treatment that improves a measurable biomarker but does nothing for a patient’s ability to work, care for their family, or live without chronic pain may pass a conventional efficacy bar while failing the people it was designed to help. Rare disease networks, which hold the concentrated expertise of patient communities, have become indispensable partners in defining endpoints that are both scientifically rigorous and genuinely meaningful – a combination that regulators now actively seek rather than merely tolerate.
Europe: Building Collaborative Infrastructure
In Europe, the regulatory engagement with rare disease networks has taken a somewhat different but equally consequential form. The European Medicines Agency developed its orphan medicinal products framework from 2000 onwards, establishing the Committee for Orphan Medicinal Products and creating adaptive pathways that acknowledged the evidentiary constraints of small-population development.
The most ambitious structural response came with the European Reference Networks (ERNs). The 24 ERNs were launched in March 2017 and included 956 highly specialised healthcare units from 313 hospitals in 26 countries. These virtual networks, established under the Cross-Border Healthcare Directive of 2011, were designed to ensure that clinical expertise could travel across borders so that patients did not have to – a principle with both humanitarian and regulatory significance. When rare disease expertise is concentrated in a handful of specialist centres distributed across a continent, the ERNs create the connective tissue through which that expertise can be pooled, standardised, and made available to regulators as a coherent evidence base rather than a fragmented collection of isolated clinical observations.
The ERNs represent something relatively new in regulatory history: a framework in which regulators did not simply receive evidence generated by others, but actively participated in building the infrastructure through which that evidence is created. That shift – from passive assessor to active network participant – is the defining characteristic of how European rare disease regulation has evolved.
Going Global: The IRDiRC and International Regulatory Convergence
The logic that drove the creation of ERNs at a European level has, over the past decade, begun to operate at a global one. No single country has enough rare disease patients to power meaningful trials alone; no single regulatory agency, however sophisticated, has the full breadth of expertise required to evaluate the full range of rare disease therapies. International regulatory convergence has therefore become both a scientific necessity and a practical priority.
The International Rare Diseases Research Consortium (IRDiRC), launched in 2011, has brought together regulatory agencies from over thirty countries alongside research funders, patient organisations, and industry. Its work on data standards, patient registry interoperability, and harmonised clinical trial methodology has created a shared language that allows evidence generated in one country to be recognised and used by regulators in another – reducing duplication, accelerating development timelines, and ultimately serving patients more efficiently.
Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), building on Japan’s long history of rare disease engagement dating back to the Nanbyo programme of 1972, has been an active participant in this global convergence, as have Health Canada and the Therapeutic Goods Administration of Australia. The lesson that each has drawn is broadly consistent: rare diseases require regulators to be collaborators, not just gatekeepers.
The Limits of Progress
None of this is to suggest that the regulatory challenges of rare disease development have been resolved. The same flexibility that allows small-population evidence to support approval also creates risks: therapies approved on limited evidence sometimes prove, in post-market studies, to be less effective or less safe than hoped.
Marks himself acknowledged the tension directly: “I would much rather take the chance that we’re occasionally going to make an error and give something an accelerated approval than have people so desperate that they’re going out and either going overseas to get unproven therapies, or using other pathways in which the FDA doesn’t have much regulatory oversight.” That willingness to accept the possibility of error in service of patients with no other options captures, with unusual candour, the judgement call that rare disease regulators face every day.
Balancing the imperative to act quickly against the obligation to ensure that approved treatments genuinely deliver what they promise remains one of the most difficult challenges in the field. Rare disease networks, by keeping patient perspectives central to evidence generation and endpoint definition, are the most effective mechanism available for ensuring that the treatments which receive regulatory approval are the ones that actually matter to the patients who need them.
A Model With Wider Implications
What regulators have learned from rare diseases is, in essence, a lesson about the limits of evidence generated entirely from above. The most rigorous assessments of rare disease therapies are those in which patients have helped define what matters, networks have pooled the data that no single centre could generate alone, and regulators have engaged early and collaboratively rather than waiting at the end of the process to pass judgement.
That rare disease model – collaborative, patient-centred, evidence-rich despite small populations – is increasingly recognised as relevant beyond rare diseases. The frameworks forged in rare disease regulation are shaping how agencies think about personalised medicine, targeted oncology, and the use of real-world evidence more broadly. In this sense, rare disease networks have done more than serve their immediate constituents. They have helped regulators become better at their job.
Next in the series: How patients and caregivers experience rare disease networks – what has been gained, and what remains missing.
